Contact Us » Site Map »
  • About Ambit
    • About Ambit
    • Leadership Team
    • Board of Directors
    • Investors
  • Product Pipeline
    • Product Pipeline
    • Quizartinib (AC220)
    • AC480
    • AC430
    • CEP32496
    • CSF1R Program
    • Kinase Discovery Expertise
    • Publications
  • Clinical Trials
  • Strategic Partnerships
    • Strategic Partnerships
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb (BMS)
    • Cephalon
  • News & Events
    • Press Releases
  • Careers
    • Opportunities
    • Recruiters

Press Releases

  •  
  •  
  •  
  •  
Print
Press Releases
2012 | 2011 | 2010 | 2009

December 16, 2011Ambit and Astellas Announce Results From Multiple Quizartinib Presentations At The 53rd Annual Meeting Of The American Hematology Society

December 1, 2011Astellas and Ambit Announce Data Presentations

November 18, 2011Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer

June 13, 2011Interim Data from Phase 2 Trial of AC220 Monotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia with FLT3-ITD Activating Mutations

June 10, 2011Ambit Biosciences Completes $30 Million Series D-2 Financing

June 9, 2011Ambit Biosciences and Astellas Announce Upcoming Presentation of AC220 Data at the 16th Annual Congress of the European Hematology Association

RSS Feed of Most Recent Press Releases

Privacy Policy » Terms & Conditions » © 2012 Ambit Biosciences Inc.
built@zoomedia